Compare SHMD & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHMD | STIM |
|---|---|---|
| Founded | 1864 | 2003 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 216.2M | 105.5M |
| IPO Year | N/A | 2018 |
| Metric | SHMD | STIM |
|---|---|---|
| Price | $6.16 | $1.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 225.2K | ★ 1.3M |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $85,165,542.00 | ★ $129,873,000.00 |
| Revenue This Year | N/A | $101.67 |
| Revenue Next Year | N/A | $10.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 78.61 |
| 52 Week Low | $1.86 | $1.25 |
| 52 Week High | $6.70 | $5.92 |
| Indicator | SHMD | STIM |
|---|---|---|
| Relative Strength Index (RSI) | 63.46 | 39.52 |
| Support Level | $5.28 | $1.26 |
| Resistance Level | $6.52 | $1.64 |
| Average True Range (ATR) | 0.62 | 0.15 |
| MACD | 0.12 | 0.03 |
| Stochastic Oscillator | 80.38 | 16.98 |
Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.